PAI-1 and atherothrombosis

J Thromb Haemost. 2005 Aug;3(8):1879-83. doi: 10.1111/j.1538-7836.2005.01420.x.


Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of tissue-type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI-1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI-1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI-1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI-1 excess promotes the development of intravascular thrombosis and atherosclerosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Atherosclerosis / metabolism*
  • Atherosclerosis / pathology
  • Cardiovascular Diseases / metabolism
  • Circadian Rhythm
  • Diabetes Mellitus, Type 2 / blood
  • Humans
  • Insulin Resistance
  • Ischemia
  • Plasminogen Activator Inhibitor 1 / blood*
  • Plasminogen Activator Inhibitor 1 / physiology*
  • Protein Structure, Tertiary
  • Thrombosis / metabolism*
  • Thrombosis / pathology


  • Plasminogen Activator Inhibitor 1